Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Other material
confidence 72%
filed 2026-05-21
Item 7.01
The disclosure reveals material clinical development information about NanoViricides' drug candidates, including that NV-387 is "now entering Phase II clinical trial against Mpox in DRC" and that the company has developed an oral formulation of remdesivir encapsulated in NV-387 nanoviricide micelles with demonstrated efficacy in animal models. The company also states it has "a clinical site in DRC for treatment of Mpox patients." This represents significant clinical progress and pipeline advancement that would affect a reasonable investor's assessment of the company's development stage and commercial prospects, but does not fit neatly into the more specific event categories (not an earnings release, executive change, M&A, impairment, or litigation).
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-05-21
Item 5.07
This Item 5.07 filing discloses the results of two shareholder votes held on May 20, 2026: a Court Meeting of Scheme Shares and a General Meeting of shareholders, both approving a Scheme of Arrangement (a merger/acquisition transaction). The overwhelming approval rates (99.98% in favor at both meetings) and the explicit statement that "All matters submitted to a vote of the Company's stockholders...were approved" directly match the shareholder_vote_results event type. This is material as it represents shareholder approval of a significant corporate transaction.
View raw filing on EDGAR →
8-K
M&A activity
confidence 99%
filed 2026-05-21
Item 1.01
AvalonBay Communities entered into a definitive merger agreement with Equity Residential in an all-stock merger-of-equals transaction at an exchange ratio of 2.793 Equity Residential shares per AvalonBay share, announced on May 21, 2026. The transaction includes governance arrangements and equity award conversions, representing a material combination of two major REITs.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-05-21
Item 2.02
John Deere Capital Corporation disclosed quarterly and year-to-date financial results for Q2 and the first six months of fiscal 2026, including revenue, net income, and ending portfolio balance, along with Deere & Company's parent company press release and supporting presentation materials.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 1.01
Mayville Engineering entered into an underwriting agreement on May 19, 2026 to issue 4,348,000 shares of common stock at $20.00 per share, plus an additional 652,000 shares from a fully exercised option, generating approximately $93.9 million in net proceeds. The offering was announced via press release filed as a Regulation FD disclosure.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-05-21
Item 8.01
S&P Global's Board approved the separation of its Mobility division through a pro rata distribution of 100% of Mobility Global shares to shareholders, with an effective date of July 1, 2026. This constitutes a material change of control and disposition event—the company is divesting a major business unit and spinning it off as an independent public company. While technically a "spin-off" rather than a traditional M&A transaction, it represents a fundamental restructuring that materially affects the registrant's asset base and shareholder value, falling squarely within the ma_activity category.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 85%
filed 2026-05-21
Item 3.02
Rigetti Computing completed an unregistered private offering of equity securities in reliance on Section 4(a)(2) and/or Regulation D exemptions, resulting in dilution to existing shareholders.
View raw filing on EDGAR →
8-K
Other material
confidence 70%
filed 2026-05-21
Item 8.01
Rigetti's wholly-owned subsidiary entered into a non-binding Letter of Intent with the U.S. Department of Commerce for a $100 million CHIPS and Science Act award over three years, contingent on negotiating definitive agreements and involving issuance of common stock to the Department at a discounted price.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces completion of an FDA meeting regarding zervimesine for dementia with Lewy bodies patients with psychosis. This represents a material regulatory milestone for a clinical-stage biopharmaceutical company, but does not fit neatly into more specific categories (not an earnings release, M&A activity, or litigation). FDA meeting outcomes can materially affect development timelines and investor expectations for drug candidates.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-21
Item 5.02
The Board appointed Glenn Wright as an independent director effective May 26, 2026, and assigned him to the Finance and Risk Management Committee. Wright is a former Shell executive with relevant energy industry experience.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-05-21
Item 5.02
John Livingston was elected and appointed as a new director of the Board effective May 19, 2026, with concurrent appointments to the Audit, Finance and Risk Committee and Compensation and Leadership Development Committee. The appointment includes an annual retainer of $50,000, committee fees, and 5,896 RSUs.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from Sierra Bancorp's annual meeting held May 20, 2026. The filing reports voting outcomes on three proposals: election of directors (with detailed vote tallies for each nominee), ratification of Forvis Mazars, LLP as independent auditor (98.23% approval), and advisory vote on executive compensation (96.38% approval). The detailed vote counts and percentages are the core content of Item 5.07, which is the standard Item for reporting shareholder meeting results.
View raw filing on EDGAR →
8-K
M&A activity
confidence 70%
filed 2026-05-21
Item 1.01
CNH Capital Receivables LLC entered into material definitive agreements (Underwriting Agreement and Trust Agreement) in connection with a $907.68 million asset-backed securitization issuance by CNH Equipment Trust 2026-B, materially affecting the registrant's capital structure and financial obligations.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from Reliance, Inc.'s Annual Meeting of Stockholders held on May 20, 2026. The filing reports voting outcomes on four matters: election of nine directors, advisory approval of named executive officer compensation, ratification of KPMG LLP as independent auditor, and a stockholder proposal on director tenure. These are routine but material governance matters that affect investor understanding of board composition and corporate oversight.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
KKR FS Income Trust Select issued 195,291.294 Class I shares for approximately $4.894 million in an unregistered private offering relying on Section 4(a)(2) of the Securities Act and Regulation D, diluting existing shareholders' ownership.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 95%
filed 2026-05-21
Item 3.02
KKR FS Income Trust issued 206,091.447 Class I shares for approximately $6.024 million in an unregistered private offering under Section 4(a)(2) of the Securities Act and Regulation D, diluting existing shareholders' ownership.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The Company disclosed its net asset value per Class I Share of $29.23 as of April 30, 2026 (aggregate NAV ~$1.582 billion) and reported that its ongoing private offering has raised $1.667 billion of a $5.0 billion target.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The filing discloses the closing of a subscription offering in connection with the conversion of Pioneer Federal Savings and Loan Association to a stock bank and the establishment of PSB Financial as its holding company, with the Company's common stock commencing quotation on OTCQB under symbol "PNSB" on May 22, 2026. While this represents a significant corporate restructuring and capital event, it does not fit neatly into the more specific event categories (it is not a traditional M&A activity, dilutive issuance, or earnings release), making "other_material" the most appropriate classification for this material conversion and initial public quotation event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from the Company's 2026 Annual Meeting of Stockholders held on May 18, 2026, filed under Item 5.07. The filing reports voting outcomes on three proposals: election of ten directors, ratification of Deloitte & Touche LLP as independent auditor, and an advisory vote on named executive officer compensation. All proposals passed with strong majorities (89–99% support), making this a material governance event that affects investor understanding of board composition and audit oversight.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from California Water Service Group's Annual Meeting of Stockholders held on May 20, 2026. The filing reports voting outcomes on three matters: (1) election of 11 directors, (2) advisory vote on named executive officer compensation, and (3) ratification of Deloitte & Touche LLP as independent auditor. This is the quintessential shareholder_vote_results event type under Item 5.07.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-05-21
Item 5.02
Shawn Canter, Chief Financial Officer of KULR Technology Group, resigned effective May 22, 2026, pursuant to a Separation Agreement. While the disclosure includes compensatory terms (severance, cooperation payments), the principal disclosed action is the departure of a named executive officer from a C-suite position, making exec_departure the most salient classification. The CFO role is material to investor assessment of the company's financial oversight and governance.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Merchants Bancorp held its Annual Meeting of Shareholders on May 21, 2026, with voting results disclosed for three matters: election of twelve directors, a non-binding advisory vote on named executive officer compensation, and ratification of Forvis Mazars, LLP as the independent auditor.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This Item 5.07 disclosure reports the results of Solid Power's 2026 annual meeting of stockholders held on May 20, 2026, including election of three Class II directors (Steven Goldberg, Aleksandra Miziolek, and MaryAnn Wright), ratification of Deloitte & Touche LLP as independent auditor, and advisory approval of named executive officer compensation. The detailed voting tallies for each matter are provided, which is the core content of a shareholder vote results disclosure.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 8.01
The disclosure announces EXIM Board approval of a $2.9 billion senior secured long-term loan to support development of the Stibnite Gold Project. While this is a material financing event that would significantly affect investor assessment of the company's capital structure and project funding, it does not fit cleanly into the standard M&A taxonomy categories. The event is neither a traditional acquisition/disposition nor a debt covenant breach or going-concern disclosure, making "other_material" the most appropriate classification for this major project financing approval.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Target Hospitality Corp. held its 2026 Annual Meeting of Stockholders on May 21, 2026, with shareholders voting on four proposals: election of six directors, ratification of Ernst & Young LLP as independent auditor, advisory say-on-pay vote on named executive officer compensation, and approval of a 4,000,000 share increase to the 2019 Incentive Award Plan. All proposals passed with substantial majorities ranging from 85.45% to 99.95% approval.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 85%
filed 2026-05-21
Item 8.01
On May 21, 2026, Target Hospitality Corp. awarded restricted stock units (RSUs) to non-employee directors, with the award agreement filed as an exhibit. This material equity compensation grant to directors reflects the company's director compensation arrangements.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Mohawk Industries held its Annual Meeting on May 21, 2026, with shareholders voting on four matters: election of three directors, ratification of KPMG LLP as independent auditor, advisory vote on named executive officer compensation, and approval of the 2026 Incentive Plan.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Rithm Capital held its Annual Meeting of Stockholders with voting results on multiple matters: election of two Class I directors (David Saltzman and William D. Addas), ratification of Ernst & Young LLP as independent auditor, advisory approval of named executive officer compensation, and approval of the First Amendment to the 2023 Omnibus Incentive Plan increasing reserved shares by 35 million.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
Citigroup held its 2026 Annual Meeting of Stockholders on May 20, 2026, with voting results disclosed on four matters: election of 13 directors, ratification of KPMG LLP as independent auditor, advisory vote on 2025 executive compensation, and approval of an amendment to the 2019 Stock Incentive Plan increasing authorized shares by 20 million.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The Company entered into a new $1.2 billion Five-Year Revolving Credit Agreement on May 15, 2026, replacing a prior $1.0 billion facility. While this represents a material refinancing and increase in available liquidity, it does not fit neatly into the more specific event categories (ma_activity applies to acquisitions/dispositions, not credit facility amendments; covenant_breach applies to violations, not new covenant establishment). The disclosure is material to investors as it affects the Company's financial flexibility and capital structure, but the event is best classified as other_material given the absence of a dedicated taxonomy entry for credit facility amendments or refinancings.
View raw filing on EDGAR →
8-K
Exec departure
confidence 92%
filed 2026-05-21
Item 5.02
C. Taylor Pickett (CEO) and Robert O. Stephenson (CFO) are departing the company, effective October 1, 2026 and August 1, 2026 respectively. The filing discloses transition and consulting agreements for both executives, representing a material change in the company's top leadership.
View raw filing on EDGAR →
8-K
Earnings release
confidence 95%
filed 2026-05-21
Item 7.01
ClearSign Technologies disclosed quarterly financial results for the quarter ended March 31, 2026 via a press release issued on May 20, 2026, along with a conference call transcript discussing the results.
View raw filing on EDGAR →
8-K
Other material
confidence 85%
filed 2026-05-21
Item 8.01
Adagio Medical submitted a Premarket Approval (PMA) application to the FDA for its vCLAS® Ventricular Ablation System, a significant regulatory milestone for a medical device company. This event is material to investors as FDA approval is a critical path to commercialization and revenue generation, but it does not fit neatly into the more specific event categories (not an earnings release, M&A activity, impairment, litigation, or other defined types). The submission of a major regulatory application represents a material corporate development warranting disclosure under Item 8.01.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-05-21
The filing discloses the appointment of Troy Taylor, age 54, to the position of Chief Operating Officer (COO) effective May 20, 2026. This is a material executive appointment under Item 5.02, as the COO is a senior officer responsible for leadership and strategic direction. The filing explicitly states no material compensatory arrangements were entered into, making the appointment itself—not compensation—the principal disclosed event.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
The filing discloses Item 5.07 results from Walker & Dunlop's 2026 Annual Meeting of Stockholders held on May 19, 2026, including voting outcomes on three matters: election of eight directors, ratification of KPMG LLP as independent auditor, and an advisory vote on executive compensation. These are standard shareholder vote results that materially inform investors about board composition and governance approvals.
View raw filing on EDGAR →
8-K
M&A activity
confidence 92%
filed 2026-05-21
Item 7.01
The filing discloses a "proposed transaction between VYNE and Yarrow" with an S-4 registration statement (File No. 333-294804) filed with the SEC, indicating a material merger or acquisition. The disclosure of an investor presentation by Yarrow Bioscience in connection with this transaction, combined with explicit references to proxy solicitation materials and stockholder voting, confirms this is M&A activity requiring 8-K disclosure under Item 1.01 or related provisions.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear disclosure of shareholder vote results from the Annual Meeting of Stockholders held on May 21, 2026, reporting the election of directors (James J. Brady, IV and Eric J. Heagy) and ratification of Wipfli LLP as independent auditor. Item 5.07 is the designated Item for shareholder vote results, and the filing presents final vote tallies for each matter submitted to stockholders.
View raw filing on EDGAR →
8-K
Other material
confidence 65%
filed 2026-05-21
Item 8.01
The filing discloses entry into material financing arrangements: an Indenture Supplement dated May 28, 2026 for issuance of "Offered Notes" and a Risk Retention Agreement among First National Bank of Omaha, First National Funding LLC, and First National Master Note Trust. While this involves debt issuance and securitization activity, the Item 8.01 classification and absence of explicit M&A language make it distinct from standard ma_activity. The disclosure of note offerings and related indenture supplements would materially affect investor assessment of the registrant's capital structure and financing activities.
View raw filing on EDGAR →
8-K
Other material
confidence 72%
filed 2026-05-21
Item 8.01
The disclosure announces initial clinical trial data (Duravelo-2) for a candidate therapeutic in metastatic urothelial cancer presented at ASCO. For a clinical-stage or development-focused biopharmaceutical company, positive or significant clinical data announcements are material to investors assessing pipeline progress and regulatory prospects. However, this does not fit neatly into the standard taxonomy categories (not earnings, M&A, impairment, litigation, etc.), warranting classification as other_material.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 5.03
GCI Liberty, Inc. changed its corporate name to Liberty Capital Corporation effective May 21, 2026, through amendments to its Articles of Incorporation and Bylaws. The name change does not affect security holders' rights, trading symbols (GLIBA, GLIBB, GLIBK), or CUSIP numbers.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 95%
filed 2026-05-21
Item 5.07
This Item 5.07 discloses the results of a special stockholder meeting held on May 21, 2026, where shareholders voted on the approval of a merger agreement with AC Residential Acquisition LP and related transactions. The Merger Proposal received overwhelming approval (76,820,975 FOR votes vs. 18,230 AGAINST), representing a material change of control event. The filing explicitly presents voting results for multiple proposals, which is the core disclosure required under Item 5.07.
View raw filing on EDGAR →
8-K
Other material
confidence 74%
filed 2026-05-21
Item 8.01
Black Diamond Therapeutics announced positive Phase 2 clinical trial results for silevertinib in frontline NSCLC patients with EGFR non-classical mutations, demonstrating a preliminary median progression-free survival of 15.2 months, an objective response rate of 60%, and no new safety signals.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This is a clear Item 5.07 disclosure of shareholder vote results from the 2026 Annual Meeting held on May 20, 2026. The filing reports voting outcomes on four proposals: election of seven directors, ratification of the independent auditor (EisnerAmper LLP), advisory vote on named executive officer compensation, and approval of a stock option exchange program. The detailed vote tallies for each proposal and nominee are the hallmark of shareholder_vote_results classification.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-21
Item 8.01
VIAVI Solutions conducted a public offering of 11,111,111 shares of common stock at $45.00 per share, with underwriters exercising an additional 1,666,666 shares under the greenshoe option, generating approximately $557.2 million in net proceeds. This is a material registered equity issuance that dilutes existing shareholders and materially affects the company's capital structure and cash position.
View raw filing on EDGAR →
8-K
Other material
confidence 75%
filed 2026-05-21
Item 3.03
CarParts.com implemented a 1-for-10 reverse stock split, effective May 25, 2026, following stockholder approval on May 11, 2026. The reverse split modifies the company's capital structure, affects share count and trading mechanics, and results in a new CUSIP number.
View raw filing on EDGAR →
8-K
M&A activity
confidence 85%
filed 2026-05-21
Item 1.01
The filing discloses entry into material definitive agreements in connection with the issuance of Asset Backed Notes by Mercedes-Benz Auto Receivables Trust 2026-1 on May 20, 2026. This represents a material securitization transaction involving the creation and issuance of structured debt securities backed by auto receivables, which constitutes a material financing activity requiring Item 1.01 disclosure.
View raw filing on EDGAR →
8-K
Dilutive issuance
confidence 92%
filed 2026-05-21
Item 8.01
CareTrust REIT completed a public offering of 12.5 million firm shares plus 1.875 million optional shares of common stock at $40.225 per share, totaling approximately 14.375 million shares. The filing discloses the underwriting agreement, exercise of the option, and forward sale agreements executed on May 20-21, 2026. This is a material dilutive equity issuance that would significantly affect shareholder ownership and the total mix of information available to investors.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
This Item 5.07 filing discloses the results of three shareholder votes at Bank7 Corp.'s annual meeting held May 20, 2026: election of seven directors, ratification of RSM US LLP as independent auditor for 2026, and advisory approval of 2025 named executive officer compensation. The detailed vote tallies (FOR, AGAINST, ABSTAIN, and broker non-votes) for each proposal are the core disclosure, which is the defining characteristic of shareholder_vote_results.
View raw filing on EDGAR →
8-K
Exec Compensation
confidence 92%
filed 2026-05-21
Item 5.02
The Board approved a new Change in Control Employment Agreement with Vincent P. Berger II, Executive Vice President and Chief Financial Officer, effective June 1, 2026, detailing severance benefits, eligibility triggers, and compensation arrangements in the event of a change in control and termination.
View raw filing on EDGAR →
8-K
Shareholder vote
confidence 98%
filed 2026-05-21
Item 5.07
HNI Corporation's annual meeting of shareholders held on May 20, 2026 resulted in the election of three directors (Hartnett, Porcellato, and Sivajee), ratification of KPMG LLP as independent auditor, and advisory approval of named executive officer compensation.
View raw filing on EDGAR →